if the treatment were to fail human trials Kard would incur additional scrutiny in the process of determining why the difference in effectiveness between species. Why risk their reputation?
Dana Farber and Beth Israel like KARD, a lot. Nearly all of the pre-clinical testing for Kevetrin was done at KARD and the INDA flew through the FDA review. FDA just completed pre-IND guidance for Prurisol and approved a Phase 2/3 start for human trials. Again, all performed by KARD. That's enough for me.
I believe that everything tested and reported by Kard is a replication of tests done by other independent scientific research facilities: LSU, UC Berkely, UCSF, Einstein, Southern Research, Etc. on various CIDES. My question is, why isn't all that testing sufficient to satisfy the FDA for efficacy, safety, and toxicology?
News 
Market Data 
Discover 
